The boards of directors of HOOKIPA Pharma Inc. and Poolbeg Pharma plc are pleased to announce that they have entered into non-binding discussions for an all-share acquisition by HOOKIPA of Poolbeg to create a strong clinical-stage biopharmaceutical company focused on developing and commercialising innovative medicines for critical unmet medical needs, with a special focus on next-generation immunotherapies for the treatment of cancer and other serious diseases. Learn more: https://lnkd.in/eXn7Essg
Poolbeg Pharma plc
Biotechnology Research
Focused on the development & commercialisation of innovative medicines. Ticker: POLB
About us
Poolbeg Pharma plc is focussed on the development and commercialisation of innovative medicines targeting serious diseases with a high unmet medical need. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to support the growth of the Company and the development of its robust pipeline of innovative products, thereby driving significant value creation. Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value. The team has been strengthened by the appointment of three former members of the Amryt Pharma plc leadership team, with the intention of repeating Amryt’s success and generating near term revenues. Poolbeg’s clinical programmes target large addressable markets including cancer immunotherapy-induced Cytokine Release Syndrome (CRS) and metabolic conditions such as obesity with the development of an oral GLP-1R agonist. It uses a cost-effective development philosophy to generate high quality data to support partnering and further development. Its AI-led discovery programmes analyse unique data from human challenge trials to identify clinically relevant drug targets and treatments, leading to faster development and greater commercial appeal.
- Website
-
https://www.poolbegpharma.com/
External link for Poolbeg Pharma plc
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- London
- Type
- Public Company
- Founded
- 2021
- Specialties
- cancer immunotherapy, oncology, GLP-1 agonist, obesity, RSV, influenza, oral vaccines, Oral GLP-1, metabolic conditions, Artificial Intelligence, and AI
Locations
-
Primary
Get directions
40 Bank Street, Floor 24
London, E14 5NR, GB
-
Get directions
Fitzwilliam Hall, Fitzwilliam Place
4th Floor
Dublin 2, D02 T292, IE
Employees at Poolbeg Pharma plc
-
Eddie Gibson
Associate at Wickenstones Ltd
-
Jeremy Skillington, PhD
Chief Executive Officer at Poolbeg Pharma
-
Brendan Buckley
Chief Medical Officer at Teckro
-
Cathal Friel
Dublin, London & Vienna, Chairman and Co-Founder at Open Orphan Plc (now hVIVO plc) & Poolbeg Pharma Plc, Co-Founder & Director at Euro Green…
Updates
-
As we close out another exciting year at Poolbeg Pharma plc, we we send our warmest holiday wishes to all of our followers, team members, investors and partners! 🎄 #MerryChristmas #POLB
-
Our Chief Business Officer David Allmond highlights that CRS is a rate limiting side effect associated with emerging cancer immunotherapies & how the oral administration of POLB 001 to prevent or treat CRS has the potential to enable broader, safer delivery of cancer immunotherapies in an outpatient setting. 🏥 Strong impact on the healthcare system & patients 👉 Few approved therapies for CRS management ⛔ No approved preventatives for CRS #Immunotherapies #Cancer #CRS
-
What is Cytokine Release Syndrome CRS? Here Dr Martin Kaiser from The Institute of Cancer Research explains... 😷Severe #inflammatory response 🌡️ Life-threatening side effect of cancer immunotherapies 🏥Leads to extended hospital stays #Cancer #Oncology #CRS #Immunotherapies #CancerTreatments #POLB
-
Our CEO Jeremy Skillington, PhD presented “p38 MAPK inhibition – novel method to prevent CRS and enable safer administration of cell therapies” at Cell & Gene Therapy International Europe in Dublin last week. We were delighted to see such high attendance at Poolbeg Pharma plc Pharma’s session and the excitement shared about the potential of POLB 001 to address cancer immunotherapy-induced CRS. #POLB #Dublin #CellTherapy #Presentation
-
-
Our POLB 001 data and poster presentation at American Society of Hematology was featured in PharmaTimes Media Ltd: 👉 "unveiled encouraging pre-clinical study data for POLB 001 at the 66th American Society of Hematology (ASH) Annual Meeting" 💪 Reinforcing POLB 001 potential in preventing & treating cancer immunotherapy-induced CRS ✅ The positive pre-clinical results underpin the development of POLB 001 for Phase 2 clinical trials as a prophylactic for immunotherapy-induced CRS Read full article here: https://lnkd.in/eg7kKHQs #POLB #PharmaTimes #ASHConference #ASH2024 #Immunotherapy #CRS
Poolbeg Pharma presents positive results for POLB 001: promising pre-clinical data on preventing cytokine release syndrome #News
-
📷 Snaps from ASH! Our CEO Jeremy Skillington, PhD presented our POLB 001 poster at the 66th American Society of Hematology Annual Meeting, the world’s leading conference on hematological malignancies. Presenting at ASH is strong validation of POLB 001’s potential and we are delighted to have had the opportunity to continue our productive partnering discussions at this prestigious conference. #ASH24 #POLB #cancer #CART #bispecific
-
We are delighted to share key insights from our POLB 001 poster presentation at the prestigious 66th American Society of Hematology Annual Meeting. The positive results from this study reinforce the use case for POLB 001 in the prevention and treatment of cancer immunotherapy-induced CRS: • Dose dependently reduced clinical CRS scores • Demonstrated superior cytokine inhibition compared to the gold standard inhibitor of CRS in humanized tumour-bearing mouse model • Statistically significant reduction of peak serum levels of TNF, IL-4, IL-6, IL-8, MIP-1α • Reduced peak serum levels of all other cytokines tested, including IFN-γ, IL-8, IL-10, IL-2 • Other immunological & malignancy-related endpoints were monitored with no harmful effects of POLB 001 observed Learn more: https://lnkd.in/e3vfjMjT #ASH24 #POLB #cancer #CART #bispecific
-
Our CEO Jeremy Skillington, PhD presenting at next weeks' Cell & Gene Therapy International Europe in Dublin. 🎤 p38 MAPK inhibition - novel method to prevent CRS and enable safer administration of cell therapies 📅 3 December 2024, 2pm This years focus is on future-proofing cell & gene therapies, to expedite advanced therapy development. We look forward to sharing insights into the potential of POLB 001 to prevent cancer immunotherapy-induced CRS with industry colleagues and potential partners. Learn more: https://lnkd.in/eeWBzXk #POLB #GeneCellTherapy #CellTherapy #Conference #Dublin